Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
2 بازدیدها
• 07/14/23
0
0
جاسازی کنید
administrator
مشترکین
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
بیشتر نشان بده، اطلاعات بیشتر
نظرات فیس بوک
SORT BY-
نظرات برتر
-
آخرین نظرات